Arachidonic acid metabolites: Mediators of inflammation in asthma

Pharmacotherapy

Volumn 17, Issue 1 SUPPL., 1997, Pages

  Wenzel, Sally E ^a  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONIC ACID DERIVATIVE; LEUKOTRIENE; MONTELUKAST; PRANLUKAST; PROSTACYCLIN; PROSTAGLANDIN; PROSTAGLANDIN D2; PROSTAGLANDIN E2; THROMBOXANE A2; ZAFIRLUKAST; ZILEUTON;

ARACHIDONIC ACID METABOLISM; ARTICLE; ASTHMA; CHEMOTAXIS; DRUG MECHANISM; HUMAN; INFLAMMATION; LEUKOCYTE MIGRATION; LEUKOCYTE MIGRATION INHIBITION; MEMBRANE PERMEABILITY; PATHOGENESIS;

ARACHIDONATE 5-LIPOXYGENASE; ARACHIDONIC ACID; ASTHMA; HUMANS; INFLAMMATION MEDIATORS; LEUKOTRIENES; PROSTAGLANDINS;

EID: 0031017337     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Laitinen LA, Laitinen A, Haahtela T. Airway mucosal inflammation even in patients with newly diagnosed asthma. Am Rev Respir Dis 1993;147:697-704.
2. Henderson WR Jr. The role of leukotrienes in inflammation. Ann Intern Med 1994;121:684-97.
3. Rouzer CA, Ford-Hutchinson AW, Morton HE, Gillard JW. MK-886, a potent and specific leukotriene biosynthesis inhibitor blocks and reverses the membrane association of 5-lipoxygenase in ionophore-challenged leukocytes. J Biol Chem 1990;265:1436-42.
4. Samuelsson B, Dahlen SE, Lindgren JA, Rouzer CA, Serhan CN. Leukotrienes and lipoxins: structures, biosynthesis and biological effects. Science 1987;237:1171-6.
5. Samuelsson B. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science 1983;220:568-75.
6. Ford-Hutchinson AW, Bray MA, Doig MV, Shipley ME, Smith MJH. Leukotriene B4, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes. Nature 1980;286:264-5.
7. Drazen JM, Austen KF, Lewis RA, Clark DA, Goto G, Marfat A, Corey EJ. Comparative airway and vascular activity of leukotriene C-1 and D in vivo and in vitro. Proc Natl Acad Sci USA 1980;77:4345-58.
8. Marom Z, Shelhamer JH, Bach MK, Morton DR, Kaliner M. The effects of arachinoids and leukotrienes on the release of mucus from human airways. Chest 1982;81:365-70.
9. 4 increase the release of mucus from human airways. Am Rev Respir Dis 1982;126:449-51.
10. Barnes NC, Piper PJ, Costello JF. Comparative actions of inhaled leukotriene C4, leukotriene D4 and histamine in normal human subjects. Thorax 1984;39:500-4.
11. Laitinen LA, Laitinen A, Haahtela T, Vilkka V, Spur BW, Lee TH. Leukotriene E4 and granulocytic infiltration into asthmatic airways. Lancet 1993;341:989-90.
12. Coleman RA, Eglen RM, Jones RL, Narumiya S, Shimizu T, Smith WL, Dahlen SE, Drazen JM, Gardiner PJ, Jackson WT, Jones TR, Krell RD, Nicosia S. Prostanoid and leukotriene receptors: a progress report from the IUPHAR working parties on classification and nomenclature. Adv Prost Throm Leuko Res 1995;23:283-5.
13. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for the aspirin-like drugs. Nature 1971;231:232-5.
14. Xie W, Chipman JG, Robertson DL, Erikson RL, Simmons DL. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA 1991;88:2692-6.
15. Seibert K, Masferrer J, Zhang Y, et al. Mediation of inflammation by cyclooxygenase-2. Agents Actions 1995; 46(suppl):41-50.
16. Hyman AL, Spannhake EW, Kadowitz PJ. Prostaglandins and the lung. Am Rev Respir Dis 1978;117:111-36.
17. Israel E, Fischer AR, Rosenberg MA, Lilly CM, Callery JC, Shapiro J, Cohn J, Rubin P, Drazen JM. The pivotal role of 5-lipoxygenase products in the reaction of aspirin sensitive asthmatics to aspirin. Am Rev Respir Dis 1993;148:1447-51.
18. Wenzel SE. Asthma as an inflammatory disease. Ann Allergy 1994;72:261-71.
19. Castells M, Schwartz LB. Tryptase levels in nasal lavage fluid as an indicator of the immediate allergic response. J Allergy Clin Immunol 1988;82:348-55.
20. Tomioka M, Ida S, Shindoh Y, Ishihara T, Takishima T. Mast cells in bronchoalveolar lumen of patients with bronchial asthma. Am Rev Respir Dis 1984;129:1000-5.
21. 4 in bronchoalveolar lavage fluid from atopic asthmatics after endobronchial allergen challenge. Am Rev Respir Dis 1990;142:112-19.
22. Wenzel SE, Westcott JY, Smith HR, Larsen GL. Spectrum of prostanoid release after bronchoalveolar challenge in atopic asthmatics and in control groups. An alteration in the ratio of bronchoconstrictive to bronchoprotective mediators. Am Rev Respir Dis 1989;139:450-7.
23. Robinson DS et al. Evidence for a predominant Th2-type bronchoalveolar lavage T lymphocyte population in atopic asthma. New Engl J Med 1991;326:298-304.
24. Kay AB Lymphocytes and their products in atopic allergy and asthma. Int Arch Allergy Appl Immunol 1991;94:189-93.
25. Burd PR, Rogers HW, Gordon JR, et al. Interleukin-3-dependent and -independent mast cells stimulated with IgE and antigen express multiple cytokines. J Exp Med 1989;170:245-57.
26. Broide DH, Lotz M, Cuomo AJ, Coburn DA, Federman EC, Wasserman SI. Cytokines in symptomatic asthma airways. J Allergy Clin Immunol 1992;89:958-67.
27. Pober J, Belivacqua M, Medrick D, et al. Two distinct monokines, interleukin-1 and tumor necrosis factor, each independently induces biosynthesis and transient expression of the same antigen on the surface of cultured human vascular endothelial cells. J Immunol 1986;136:1680-7.
28. 4 and tumor necrosis factor alpha levels in bronchoalveolar lavage fluid and pulmonary alveolar macrophages [abstr]. Am J Respir Crit Care Med 1995; 151:136A.
29. Gleich GJ, Frigas E, Loegering DA, Wassom DL, Steinmuller D. Cytotoxic properties of the eosinophil major basic protein. J Immunol 1979;123:2925-7.
30. Wegner CD, Gundel RH, Reilly P, Haynes N, Letts LG, Rothlein R. Intercellular adhesion molecule-1 (ICAM-1) in the pathogenesis of asthma. Science 1990;247:456-9.
31. Gosset P, Tillie-Leblond I, Janin A. Increased expression of ELAM-1, ICAM-1 and VCAM-1 on bronchial biopsies from allergic asthmatic patients. Ann NY Acad Sci 1994;725: 163-172.
32. Taylor IK, O'Shaughnessy KM, Fuller RW, Dollery CT. Effect of cysteinyl-leukotriene receptor antagonist ICI 204,219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects. Lancet 1991;337:690-4.
33. 4 receptor antagonist, in subjects with bronchial asthma. Am J Respir Crit Care Med 1994;150:618-23.
34. Wenzel SE, Trudeau JB, Kaminsky DA, Cohn J, Martin RJ, Westcott JY. Effect of 5-lipoxygenase inhibition on bronchoconstriction and airway inflammation in nocturnal asthma. Am J Respir Crit Care Med 1995;152:897-905.
35. Pavord ID, Wong CS, Williams J, Tattersfield AE. Ellect of inhaled prostaglandin E2 on allergen-induced asthma. Am Rev Respir Dis 1993;148:87-90.
36. Alam R, Dejarnatt A, Stafford S, Forsythe PA, Kumar D, Grant JA. Selective inhibition of the cutaneous late but not immediate allergic response to antigens by misoprostol, a PGE analog. Results of a double-blind, placebo-controlled randomized study. Am Rev Respir Dis 1993;148:1066-70.
37. Bousquet J, Chanez P, Lacoste J, et al. Eosinopnilic inflammation in asthma. N Engl J Med 1990;323:1033-9.
38. 4 from the urine of patients with airway obstruction. Am Rev Respir Dis 1992;146:104-8.
39. Taylor G, Taylor I, Black P, et al. Urinary leukotriene E4 after allergen challenge and in acute asthma and allergic rhinitis. Lancet 1989;1:584-8.
40. 4 in the assessment of nocturnal asthma. J Allergy Clin Immunol 1996;97:735-41.
41. Diaz P, Gonzalez M, Galleguillos F, et al. Leukocytes and mediators in bronchoalveolar lavage during allergen-induced late-phase asthmatic reactions. Am Rev Respir Dis 1989;139:1383-9.
42. Dahlen B, Margolskee DJ, Zetterstrom O, Dahlen SE. Effect of the leukotriene receptor antagonist MK-0679 on baseline pulmonary function in aspirin sensitive asthmatic subjects. Thorax 1993;48:1205-10.